Showing results (761-770 of 836) with videos related to

Sort By:
Pageof 84
Diabetes Research and Clinical Practice|October 7, 2023
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trialHiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, et al.
Diabetes Care|July 10, 2021
Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 DiabetesFarsad Afshinnia, Thekkelnaycke M Rajendiran, Chenchen He, et al.
Kidney International Reports|May 2, 2022
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic RegionsPriya Vart, Ricardo Correa-Rotter, Fan Fan Hou, et al.
Cardiovascular Diabetology|April 18, 2025
Sex differences in myocardial flow reserve among individuals with type 2 diabetes: insights from the DiaHeart studyAnne-Cathrine Skriver-Møller, Philip Hasbak, Ida K B Rasmussen, et al.
Diabetes Research and Clinical Practice|October 20, 2022
Baseline risk markers and visit-to-visit variability in relation to kidney outcomes - A post-hoc analysis of the PERL studyViktor Rotbain Curovic, Neil Roy, Tine W Hansen, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 12, 2024
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K Judge, Katherine R Tuttle, Natalie Staplin, et al.
The New England Journal of Medicine|March 4, 2026
Finerenone in Type 1 Diabetes and Chronic Kidney DiseaseHiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, et al.
Diabetes, Obesity & Metabolism|February 16, 2021
Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trialJoseph G Timmons, Nicola Greenlaw, James G Boyle, et al.
European Heart Journal|August 30, 2024
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trialKenneth W Mahaffey, Katherine R Tuttle, Mustafa Arici, et al.
Pageof 84